Tumor DNA in plasma of breast cancer patients. Relation to treatment

Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer

“…A total of 263 publications were found using the predefined search terms, of which 8 studies (3.0%) were eligible for inclusion. Five (62.5%) prospective population studies were included, [18][19][20][21][22] whereas the remaining 3 (37.5%) studies were retrospective cohort studies. 11,23,24 All studies were published between 2002 and 2020.…”

“…The other 5 studies reported ctDNA levels and DFS for patients with early breast cancer. [18][19][20]22,24 The timing of ctDNA sampling also varied between studies. Five studies collected ctDNA samples before starting treatment (surgical or oncologic), 11,18,[22][23][24] whereas 3 studies recorded ctDNA after commencing treatment to predict oncologic outcomes.…”

“…[18][19][20]22,24 The timing of ctDNA sampling also varied between studies. Five studies collected ctDNA samples before starting treatment (surgical or oncologic), 11,18,[22][23][24] whereas 3 studies recorded ctDNA after commencing treatment to predict oncologic outcomes. [19][20][21] Quantification and measurement of ctDNA levels varied between the studies.…”

“…The remaining 5 studies examined early breast cancer disease and reported a delta trend in ctDNA over time. [18][19][20]22,24 Circulating tumor DNA gene variation detection was reported as a poor prognostic indicator of DFS.…”

“…Similarly, Ma et al 23 and Chen et al 19 examined both the TP53 and PIK3CA gene variations as well as MTOR and AKT1, respectively. Garcia-Murillas et al 18 analyzed PIK3CA exclusively, whereas Silva et al 22 studied the TP53 mutation. The remaining 3 studies examined ESR1, RASSF1A, and single nucleotide variants, respectively.…”